Auday Abd Al-Razaq Al-Husseiny (1)
Inflammatory effects are caused by eosinophils, which are activated by allergens. Persistent airflow restriction is caused by ongoing airway remodeling and eosinophilic airway inflammation Although recent studies have failed to confirm this as a measure of severe asthma among adult asthma patients, high blood eosinophil levels were linked to severe asthma. Therefore, this study's goal was to ascertain whether a high blood eosinophil count and the severity of asthma are related. In 2024, a cross-sectional poll was carried out from January to December. A pre-tested structured questionnaire was used to collect data on clinical, behavioral, and sociodemographic traits. Four milliliters of venous blood were extracted from asthmatic patients in order to perform a complete blood count and assess peripheral morphology. Fifty-five (55.0%) of the 100 patients that were included in the trial were female, and forty-five (45.0%) were male. They ranged in age from 13 to 70. The range of the absolute eosinophil count was 70/mm3 to 1400/mm3. According to the severity criteria for asthma, 15 patients (15.0%) had severe asthma, 56 patients (56.0%) had moderate asthma, and 29 patients (20.0%) had mild asthma. This study aimed to evaluate the relationship between the eosinophil count in the blood and the severity of the illness. However, the study discovered a link between these two variables, indicating a relationship between peripheral eosinophil count and asthma severity.
Highlights:
[1] D. S. Postma, H. K. Reddel, N. H. ten Hacken, and M. van den Berge, “Asthma and chronic obstructive pulmonary disease: similarities and differences,” Clinics in Chest Medicine, vol. 35, no. 1, pp. 143–156, Mar. 2014.
[2] T. Vos et al., “Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013,” The Lancet, vol. 386, no. 9995, pp. 743–800, Aug. 2015.
[3] M. Loxham, D. E. Davies, and C. Blume, “Epithelial function and dysfunction in asthma,” Clin. Exp. Allergy, vol. 44, no. 11, pp. 1299–1313, Nov. 2014.
[4] J. A. Castro-Rodriguez, E. Forno, C. E. Rodriguez-Martinez, and J. C. Celedón, “Risk and protective factors for childhood asthma: what is the evidence?,” J. Allergy Clin. Immunol. Pract., vol. 4, no. 6, pp. 1111–1122, Nov. 2016.
[5] M. Kubo, “Mast cells and basophils in allergic inflammation,” Curr. Opin. Immunol., vol. 54, pp. 74–79, Oct. 2018.
[6] R. Jankowski, C. Rumeau, P. Gallet, and D. T. Nguyen, “Nasal polyposis (or chronic olfactory rhinitis),” Eur. Ann. Otorhinolaryngol. Head Neck Dis., vol. 135, no. 3, pp. 191–196, Jun. 2018.
[7] Global Initiative for Asthma/WHO Initiative. [Online]. Available: http://www.ginasthma.com/index.asp
[8] A. Moeller et al., “Monitoring asthma in childhood: lung function, bronchial responsiveness and inflammation,” Eur. Respir. Rev., vol. 24, no. 136, pp. 204–215, May 2015.
[9] K. Nakagome and M. Nagata, “Involvement and possible role of eosinophils in asthma exacerbation,” Front. Immunol., vol. 9, p. 2220, Sep. 2018.
[10] M. W. Johansson, “Activation states of blood eosinophils in asthma,” Clin. Exp. Allergy, vol. 44, no. 4, pp. 482–498, Apr. 2014.
[11] C. N. McBrien and A. Menzies-Gow, “The biology of eosinophils and their role in asthma,” Front. Med., vol. 4, p. 93, Jun. 2017.
[12] S. Saglani and C. M. Lloyd, “Novel concepts in airway inflammation and remodeling in asthma,” Eur. Respir. J., vol. 46, no. 6, pp. 1796–1804, 2015.
[13] S. S. Possa, E. A. Leick, C. M. Prado, M. A. Martins, and I. F. L. C. Tibério, “Eosinophilic inflammation in allergic asthma,” Front. Pharmacol., vol. 4, p. 46, 2013.
[14] D. Price et al., “Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice,” J. Asthma Allergy, vol. 9, pp. 1–12, 2016.
[15] D. Talini et al., “Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study,” BMJ Open, vol. 5, no. 1, p. e005748, 2015.
[16] R. S. Zeiger et al., “Blood eosinophil count and outcomes in severe uncontrolled asthma: a prospective study,” J. Allergy Clin. Immunol. Pract., vol. 5, no. 1, pp. 144–153, 2017.
[17] S. Khurana, A. Bush, and F. Holguin, “Management of severe asthma: summary of the European Respiratory Society/American Thoracic Society task force report,” Breathe, vol. 16, no. 2, 2020.
[18] B. Lalrinpuia, “Study on absolute eosinophil count correlation with severity of bronchial asthma,” 2019.
[19] L. E. Katz, G. J. Gleich, B. F. Hartley, S. W. Yancey, and H. G. Ortega, “Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma,” Ann. Am. Thorac. Soc., vol. 11, no. 4, pp. 531–536, 2014.
[20] X. Y. Zhang et al., “Full blood count parameters for the detection of asthma inflammatory phenotypes,” Clin. Exp. Allergy, vol. 44, no. 9, pp. 1137–1145, 2014.
[21] E. P. Rönmark et al., “Different risk factor patterns for adult asthma, rhinitis, and eczema: results from West Sweden Asthma Study,” Clin. Transl. Allergy, vol. 6, p. 28, 2016.
[22] J. Pakkasela et al., “Age-specific incidence of allergic and non-allergic asthma,” BMC Pulm. Med., vol. 20, no. 1, p. 9, 2020.
[23] K. Warm et al., “Allergic sensitization is age-dependently associated with rhinitis, but less so with asthma,” J. Allergy Clin. Immunol., vol. 136, no. 6, pp. 1559–1565.e2, 2015.
[24] I. Eguiluz-Gracia et al., “Recent developments and highlights in biomarkers in allergic diseases and asthma,” Allergy, vol. 73, no. 12, pp. 2290–2305, 2018.
[25] P. J. Sterk and A. Sinha, “Emerging complexity in the biomarkers of exacerbation-prone asthma,” Am. Thorac. Soc., pp. 915–917, 2020.
[26] I. D. Pavord et al., “Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomized controlled trial,” Lancet Respir. Med., vol. 8, no. 7, pp. 671–680, 2020.
[27] L. C. Denlinger et al., “Inflammatory and comorbid features of patients with severe asthma and frequent exacerbations,” Am. J. Respir. Crit. Care Med., vol. 195, no. 3, pp. 302–313, 2017.
[28] M. C. Peters et al., “Evidence for exacerbation-prone asthma and predictive biomarkers of exacerbation frequency,” Am. J. Respir. Crit. Care Med., vol. 202, no. 7, pp. 973–982, 2020.
[29] H. Kimura et al., “Prospective predictors of exacerbation status in severe asthma over a 3-year follow-up,” Clin. Exp. Allergy, vol. 48, no. 9, pp. 1137–1146, 2018.
[30] P. G. Gibson, “Variability of blood eosinophils as a biomarker in asthma and COPD,” Respirology, vol. 23, no. 1, 2018.
[31] C. E. Brightling et al., “TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis,” J. Allergy Clin. Immunol., vol. 110, no. 6, pp. 899–905, Dec. 2002.
[32] A. Malinovschi, J. A. Fonseca, T. Jacinto, K. Alving, and C. Janson, “Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects,” J. Allergy Clin. Immunol., vol. 132, no. 4, pp. 821–827, 2013.
[33] M. W. Johansson, “Activation states of blood eosinophils in asthma,” Clin. Exp. Allergy, vol. 44, no. 4, pp. 482–498, 2014.
[34] S. L. Spector and R. A. Tan, “Is a single blood eosinophil count a reliable marker for ‘eosinophilic asthma’?,” J. Asthma, vol. 49, no. 8, pp. 807–810, 2012.
[35] N. Ullmann et al., “Blood eosinophil counts rarely reflect airway eosinophilia in children with severe asthma,” Allergy, vol. 68, no. 3, pp. 402–406, 2013.
[36] S. G. Trivedi and C. M. Lloyd, “Eosinophils in the pathogenesis of allergic airways disease,” Cell. Mol. Life Sci., vol. 64, no. 10, pp. 1269–1289, 2007.
[37] K. F. Chung et al., “International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma,” Eur. Respir. J., vol. 43, no. 2, pp. 343–373, 2014.